Repaglinide |
Catalog No.GC16036 |
La repaglinida es un secretagogo de insulina para el tratamiento de la diabetes mellitus tipo 2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 135062-02-1
Sample solution is provided at 25 µL, 10mM.
Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].
Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1].
Repaglinide (AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective (P<0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.
References:
[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476.
Average Rating: 5
(Based on Reviews and 8 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *